Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2007
06/20/2007CN1321573C Bactericides
06/20/2007CA2531260A1 Method of using chitosan to reduce shedding of e. coli from bovines
06/20/2007CA2530904A1 Pharmaceutical agents for the treatment of pain associated with spinal cord injury
06/19/2007US7232929 Amide derivatives of 2,2,3,3-tetramethylcyclopropane carboxylic acid
06/19/2007US7232924 Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
06/19/2007US7232919 Platinum compounds
06/19/2007US7232912 For therapy of cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis
06/19/2007US7232909 Pyridine derivatives
06/19/2007US7232907 Reacting compounds such as 7-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid with 4-Aminomethyl-3-methoxyimino-pyrrolidinium dimethanesulfonate in presence of triethylamine or a tetraC1-6alkylammonium hydroxide, and an aqueous solvent
06/19/2007US7232906 Kinase inhibitors; antiinflammatory agents; respiratory system disorders; cardiovascular disorders; antidiabetic agents
06/19/2007US7232901 For preparing 2,4-disubstituted pyrrolotriazine compounds
06/19/2007US7232897 Administering to mammal an inhibitor of NH2-terminal Jun Kinase (JNK), wherein inhibitor is SP600125 for therapy of insulin resistance in a mammal
06/19/2007US7232847 4-aminocyclohexanones are reduced with methoxytriphosphonium chloride and sodium hydride, then with HCl, producing aldehydes; etherifying the alcohol with trimethylchlorosilane; active at opioid receptors such as the mu receptor; analgesics
06/19/2007US7232846 endogenic polyamines (putrescine, spermidine, spermine), 1,3-propanediamine, their salts and solvates, bioprecursor amides for therapeutical and prophylactic treatment of alcoholism in a human
06/19/2007US7232845 Active substance combinations comprising insecticidal and acaricidal properties
06/19/2007US7232844 Insect repellent compounds
06/19/2007US7232843 Compositions containing C-substituted diindolylmethane compounds
06/19/2007US7232842 Kinase inhibitors and associated pharmaceutical compositions and methods of use
06/19/2007US7232841 N-{4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexyl}-2-[2-({4-[2-(1,2,3,4-tetrahydro-1,4-epiazano-naphthalen-9-yl)-ethyl]-cyclohexylcarbamoyl}-methyl)-phenyl]-acetamide; treating COPD
06/19/2007US7232840 comprises a mixture with fungicidally active compounds, except for cyclopropylcarboxamide derivatives and azolylmethylcycloalkanes
06/19/2007US7232839 4-hydroxy-2-phenyl-1,2-benzisothiazol-3(2H)-one; for topical application to the skin for dry and/or mature skin
06/19/2007US7232838 2-amino-4,5-trisubstituted thiazolyl derivatives
06/19/2007US7232837 Decongestants; attention deficit disorders; dietetics; hypotensive agents; competitive binding
06/19/2007US7232835 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists
06/19/2007US7232834 Quinolylpropylpiperidine derivatives, intermediates and compositions containing them, and preparation therefor
06/19/2007US7232833 For therapy and prophylaxis of bacterial infections
06/19/2007US7232832 Antibacterial agents
06/19/2007US7232831 Tetrahydro-β-carboline compounds and use thereof
06/19/2007US7232830 Administering to a patient a compound for increasing neuronal metabolism of histamine to a histamine H2 agonist, to stimulate production of adenosine 3*,5*- cyclic phosphate at a level which maintains myelin against self degeneration
06/19/2007US7232829 Analgesics; anticonvulsants; hypotensive agents; brain damage; antiarrhythmia agents; opioid receptors
06/19/2007US7232828 PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
06/19/2007US7232827 Heteroaryl substituted 2-pyridinyl and 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one derivatives
06/19/2007US7232826 Tyrosine kinase inhibitors
06/19/2007US7232825 Drugs for treatment for diseases such as cancer using tyrosine kinases and enzyme inhibitors
06/19/2007US7232824 Used for treating disorders with enhanced activity of transforming growth factor beta TGF- beta, kidney disorders associated with unregulated TGF- beta activity and excessive fibrosis including glomerulonephritis (GN), mesangial proliferative GN, immune GN, and crescentic GN
06/19/2007US7232823 such as 1-[2-(2-chloro-phenyl)-3-(4-fluoro-phenyl)-2H-pyrazolo[3,4-d]pyridazin-7-yl]-4-isopropylamino-piperidine-4-carboxylic acid amide; for treatment of eating disorders and psychological disorders
06/19/2007US7232822 E.g., perhydrotriazino[1,2-a]piperazinediones, used for drug screening, diagnoses and treating disorders modulated by Wnt-signaling pathway, such as cancer, restenosis associated with angioplasty, polycystic kidney disease, aberrant angiogenesis disease, rheumatoid arthritis, tuberous sclerosis complex
06/19/2007US7232821 (2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives
06/19/2007US7232820 Thiadiazole-amine compounds for the treatment of neurodegenerative disorders
06/19/2007US7232819 Dihydroxypyrimidine carboxamide inhibitors of HIV integrase
06/19/2007US7232818 Compounds for enzyme inhibition
06/19/2007US7232817 α- and β-amino acid hydroxyethlamino sulfonyl urea derivatives useful as retroviral protease inhibitors
06/19/2007US7232816 Phosphodiesterase inhibitors; used to treat inflammatory conditions, allergies such as rhinitis, respiratory system disorders and cancer
06/19/2007US7232815 Dibenzo[b.f]oxazolo-azulines, -oxepines and -thiepines; antiinflammatories; analgesics
06/19/2007US7232814 Heterocyclic carboxy amines such as 9-nitro-7,12-dihydroindolo (3,2-d)(1)-benzazepin-6(5H)-one, used as inhibitors of glycogen synthase kinase-3 beta or cyclin dependent kinases
06/19/2007US7232813 Neutral endopeptidase (NEP) and human soluble endopeptidase (hSEP) inhibitors for prophylaxis and treatment of neuro-degenerative disorders
06/19/2007US7232812 Substituted azetidine compounds, their preparation and use as medicaments
06/19/2007US7232811 Furosemide modulators of HM74
06/19/2007US7232810 Characterized by minimal bone calcium mobilization activity and relatively high intestinal calcium transport activity; used to treat renal osteodystrophy, osteoporosis, autoimmune diseases such as multiple sclerosis, cancer and psoriasis
06/19/2007US7232809 Mitochondrially targeted antioxidants
06/19/2007US7232807 An RNA molecule having a sequence portion that has affinity to at least one consensus sequence present in an agglomeration nucleic acid-binding protein; detection of affinity complex formed confirms diagnoses of diseases such as spongiform encephalopathies
06/19/2007US7232805 Cobalamin conjugates for anti-tumor therapy
06/19/2007US7232799 Mixtures of a modified group A streptogramin containing an oxazole ring with a natural, semi-synthetic or synthetic group B streptogramin, e.g., pristinamycin IA, pristinamycin IB, IC, ID, IE, IF, or IG; virginiamycin S1, S3, S4, B, or C; or etamycin; low toxicity
06/19/2007US7232690 Adding a target to mixture and forming a complex of target and at least one active chemical substance of the mixture,separating the complex from the inactive chemical substances of the mixture, andeitherliberating and isolating and/or identifying at least one active chemical substance
06/19/2007US7232670 Therapy lysosomal storage disorder other than Fabry Disease caused by a deficiency of a specific protein comprising: producing protein or an active fragment thereof in an insect cell culture, administering the protein
06/19/2007US7232580 Use of extracts of Ginkgo biloba for preparing a medicament intended to treat sarcopenia
06/19/2007US7232579 Composition containing a marine-derived inorganic substance and chitin/chitosan, and method of producing the composition
06/19/2007US7232578 Acidifying urine in which the concentration of creatinine is 1.2-3.7 g/l; filtering, adsorbing and solvent extracting to purify; diluting with water; and removing pyrogens by ultrafiltration to prepare PP-0 and OA-0.79 differentiation inducers
06/19/2007US7232577 Readily dispersible dietary fiber composition
06/19/2007US7232575 Nutrient supplements and methods for treating autism and for preventing the onset of autism
06/19/2007US7232574 Uniform distribution of a long chain alcohol such as policosanol or octacosanol in a food by dissolving or suspending the alcohol in an edible oil containing less than 12 weight % linolenic acid that is free of C8-10 fatty acid triglycerides and combining the product with the food; emulsifier-free
06/19/2007US7232572 Methods of treating rosacea
06/19/2007US7232570 ERAAP modulators regulate immune responses
06/19/2007US7232568 Compositions and methods for treating hyperimmune response in the eye
06/19/2007US7232560 Enhancing the heat and/ or oxidation stability of a para-methoxy cinnamic ester with delta-tocopherol
06/19/2007CA2482021C Removal of adenine during a process of pathogen reducing blood and blood components
06/19/2007CA2437468C Sensitization of chemotherapeutic agent resistant neoplastic cells with reovirus
06/19/2007CA2316888C Methods of inactivating bacteria including bacterial spores
06/19/2007CA2304624C Tetrahydrofuran phosphate- and hydroxy esters, as prodrugs for the corresponding antifungal agent
06/19/2007CA2283322C Starter kit containing nicotinic acid compositions
06/19/2007CA2283159C Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
06/19/2007CA2281844C Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
06/19/2007CA2276429C Compositions for the treatment of ards or irds containing 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide and lung surfactant
06/19/2007CA2271940C Novel phenanthridinium derivatives
06/19/2007CA2259194C Transdermal compositions containing levosimendan
06/19/2007CA2238621C Novel drug for relieving pain and promoting the removal of calculi in urolithiasis
06/19/2007CA2185826C Peptide fragments of microbial stress proteins and pharmaceutical composition made thereof for the treatment and prevention of inflammatory diseases
06/19/2007CA2182939C A rapidly disintegrating medicinal form of tramadol or a tramadol salt
06/19/2007CA2166179C Use of a tnf-alpha antagonist in a cosmetic, pharmaceutical or skincare composition and composition thus obtained
06/19/2007CA2159112C Anti-microbial agents and screening method therefor
06/19/2007CA2159005C Method and apparatus for encapsulation of biologically-active substances in cells
06/19/2007CA2066738C Prevention, treatment and amelioration of a pathology characterized by brain inflammation
06/19/2007CA2013582C Method for enhancing transmembrane transport of exogenous molecules
06/16/2007WO2007070067A1 Regeneration of vaginal tissue with non-systemic vaginal administration of estrogen
06/16/2007CA2578790A1 Regeneration of vaginal tissue with non-systemic vaginal administration of estrogen
06/15/2007CA2536548A1 Method of enhancing reproductive function of mammals by feeding of conjugated linoleic acids
06/15/2007CA2530345A1 Composition and method for mitigating a negative effect of alcohol consumption
06/14/2007WO2007068007A1 Use of a disinfectant for treating respiratory tract infections
06/14/2007WO2007067994A1 Inhibitors of histone deacetylase for the treatment of disease
06/14/2007WO2007067993A1 Inhibitors of histone deacetylase for the treatment of disease
06/14/2007WO2007067981A2 RNA INTERFERENCE MEDIATED INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
06/14/2007WO2007067957A1 Structural carotenoid analogs or derivatives for the modulation of systemic and/or target organ redox status
06/14/2007WO2007067906A2 Peptide deformylase inhibitors
06/14/2007WO2007067904A2 Peptide deformylase inhibitors
06/14/2007WO2007067875A2 Pyridinyl sulfonamide modulators of chemokine receptors
06/14/2007WO2007067817A1 Abca1 elevating compounds
06/14/2007WO2007067814A2 Targeting gli proteins in human cancer by small molecules
06/14/2007WO2007067812A2 Protein kinase modulation by hops and acacia products
06/14/2007WO2007067807A1 Tetracyclines for treating ocular diseases and disorders
06/14/2007WO2007067781A2 9-membered heterobicyclic compounds as inhibitors of protein kinases